Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Thomas Website

Craig J. Thomas, Ph.D.

Selected Publications

1)  Jiang J, McCoy JG, Shen M, Leclair CA, Huang W, Negri A, Li J, Blue R, Harrington AW, Naini S, David G, Choi W, Volpi E, Fernandez J, Babayeva M, Nedelman MA, Filizola M, Coller BS, Thomas CJ.
A novel class of ion displacement ligands as antagonists of the aIIbß3 receptor that limit conformational reorganization of the receptor.
Bioorg. Med. Chem. Lett. 24: 1148-53, 2014.
2)  Thomas CJ, McKew JC.
Editorial: Playing Well with Others! Initiating and Sustaining Successful Collaborations between Industry, Academia and Government.
Curr Top Med Chem. 14: 291-3, 2014.
3)  Shukla S, Chufan EE, Singh S, Skoumbourdis AP, Kapoor K, Boxer MB, Duveau DY, Thomas CJ, Talele TT, Ambudkar SV.
Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna(®)) with the human ABC drug transporter P-glycoprotein.
Leukemia. 28: 961-4, 2014.
4)  Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang J, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CP, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ.
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
Proc. Natl. Acad. Sci. U.S.A. 111: 2349-54, 2014.
5)  Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.
Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
Bioorg. Med. Chem. Lett. 24: 630-5, 2014.
6)  Jain N, Miu B, Jiang J, McKinstry KK, Prince A, Swain SL, Greiner DL, Thomas CJ, Sanderson MJ, Berg LJ, Kang J.
CD28 and ITK signals regulate autoreactive T cell trafficking.
Nat. Med. 19: 1632-7, 2013.
7)  Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP.
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Proc. Natl. Acad. Sci. U.S.A. 110: 6109-14, 2013.
8)  Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorg. Med. Chem. Lett. 23: 4398-403, 2013.
9)  Chen J, Feigenbaum L, Awasthi P, Butcher DO, Anver MR, Golubeva YG, Bamford R, Zhang X, St Claire MB, Thomas CJ, Discepolo V, Jabri B, Waldmann TA.
Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Ra.
Proc. Natl. Acad. Sci. U.S.A. 110: 13534-9, 2013.
10)  McDonnell SR, Hwang SR, Rolland D, Murga-Zamalloa C, Basrur V, Conlon KP, Fermin D, Wolfe T, Raskind A, Ruan C, Jiang JK, Thomas CJ, Hogaboam CM, Burant CF, Elenitoba-Johnson KS, Lim MS.
Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma.
Blood. 122: 958-68, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 5/19/2014.